

REDCap Survey

0. Have you prescribed buprenorphine for opioid use disorder (OUD) in the past 6 months?

☐ No ☐ Yes

A. Program Characteristics

For all relevant questions, please assume that the term “buprenorphine” includes buprenorphine/naloxone combination products as well as mono formulations.

A1. Where is your clinical practice located?

State:

County:

City:

A2. Are you affiliated with an academic institution (college/university)? ☐ No ☐ Yes

A3. Does your clinic offer other medications for OUD?

Methadone?: ☐ No ☐ Yes

Extended-release naltrexone?: ☐ No ☐ Yes

A4. About how many patients with opioid use disorder (OUD) do you prescribe buprenorphine for **per month**? _____

B. Experience with Precipitated Withdrawal During Buprenorphine Induction

This survey asks about your patients' experience of precipitated withdrawal during buprenorphine induction during the last 6 months. We define patient-reported precipitated withdrawal as patient-reported new-onset or worsening withdrawal symptoms following buprenorphine administration. We define observed precipitated withdrawal as any increase in COWS score OR an increase in clinician observed opioid-withdrawal symptoms following buprenorphine administration.

B1. How does YOUR practice define observed buprenorphine-precipitated withdrawal? (Please select all that apply)

☐ An increase in COWS score

☐ An increase in opioid-withdrawal symptoms

☐ Other (Specify):

B2. During the last 6 months, have patients declined buprenorphine treatment due to reported concern about precipitated withdrawal? ☐ No ☐ Yes

B3. Have you made any changes to your buprenorphine induction protocol(s) for patients who self-report use of fentanyl? ☐ No ☐ Yes [IF NO, SKIP TO B4]

B3.1 Please select all changes made:

- ☐ An increase in the COWS score needed for induction
- ☐ An increase in the amount of time since prior use before starting buprenorphine
- ☐ A change in the initial induction dose of buprenorphine
- ☐ Other (Specify):

B4. During the last 6 months, have any of your patients experienced precipitated withdrawal based on observation or patient report?

- ☐ No ☐ Yes [IF NO, SKIP TO SECTION C]

B5. How many patients have you initiated on buprenorphine induction in the past 6 months?

B6. During the last 6 months, around what percentage of your patients have experienced precipitated withdrawal based on observation or patient report? _____

B6.1. During the last 6 months, about what percent of these patients experienced precipitated withdrawal based on:

	Estimated%
a. Observation by you during induction	<input type="checkbox"/> 0% <input type="checkbox"/> 1-9% <input type="checkbox"/> 10-49% <input type="checkbox"/> >50%
b. Patient report during home induction prescribed by you	<input type="checkbox"/> 0% <input type="checkbox"/> 1-9% <input type="checkbox"/> 10-49% <input type="checkbox"/> >50%
c. Patient report during past buprenorphine induction by other provider(s)	<input type="checkbox"/> 0% <input type="checkbox"/> 1-9% <input type="checkbox"/> 10-49% <input type="checkbox"/> >50%
d. Patient report when using illicit buprenorphine not supervised by a provider	<input type="checkbox"/> 0% <input type="checkbox"/> 1-9% <input type="checkbox"/> 10-49% <input type="checkbox"/> >50%

B7. How long ago did your practice begin seeing patients on fentanyl who were experiencing precipitated withdrawal based on observation or patient report?

- ☐ Less than 6 months; ☐ 6 months to 1 year; ☐ 1 to 2 years; ☐ 2 to 3 years; ☐ 3 to 4 years; ☐ ≥ 5years

B8. What steps have taken when patients have experienced severe precipitated withdrawal? (Check all that apply)

- ☐ Provided “comfort” (ancillary) medications (i.e., medications to treat withdrawal symptomatically, such as clonidine)
- ☐ Sent patient to ER
- ☐ Had them come into the office
- ☐ Other (Specify):

C. Buprenorphine Induction Protocol

Microdose/ultra-low dose Protocol

C1. Do you use a “microdose/ultra-low dose” buprenorphine induction protocol (i.e., defined as a starting buprenorphine dose of < 2mg)? ☐ No ☐ Yes [IF NO, SKIP TO C2]

For the “microdose/ultra-low dose” protocol:

C1.1. What patient characteristics trigger the use of this protocol? Please select all that apply:

- ☐ Past history of precipitated withdrawal with buprenorphine induction/use
- ☐ Patient reports fentanyl use/has fentanyl-positive urine drug screen
- ☐ Patient is on a long-acting opioid (e.g., methadone)
- ☐ Patient is hospitalized
- ☐ Patient is medically compromised
- ☐ Patient is pregnant
- ☐ Other (Specify):

C1.2. What is the first buprenorphine dose typically used for the “microdose/ultra-low dose” protocol? _____ mg

C1.3. Are “comfort” (ancillary) medications offered as part of this protocol? ☐ No ☐ Yes

C1.4. Following the “microdose/ultra-low dose” protocol schedule, how many days does it take to reach a 16 mg dose of buprenorphine: _____ days

C1.5. During the last 6 months, what % of patients initiated on buprenorphine have been initiated with the “microdose/ultra-low dose” protocol? ☐ 0% ☐ 1-9% ☐ 10-49% ☐ >50%

C1.6. Approximately what % of participants inducted using the “microdose/ultra-low dose” protocol have been successfully inducted (e.g., reached target dose of buprenorphine for buprenorphine-maintenance)? ☐ 0% ☐ 1-9% ☐ 10-49% ☐ >50%

C1.7. Approximately what % of participants inducted using the “microdose/ultra-low dose” protocol have experienced precipitated withdrawal? ☐ 0% ☐ 1-9% ☐ 10-49% ☐ >50%

Standard Office-based/Observed Protocol

C2. Do you use a “standard” buprenorphine induction protocol (i.e., defined as a buprenorphine starting dose of ≥ 2 mg)? ☐ No ☐ Yes [IF NO SKIP TO C3]

C2.1. At what COWS score do you typically start an induction in a non-pregnant patient without renal or hepatic dysfunction?

- ☐ I do not use COWS scores
- ☐ >8
- ☐ >10
- ☐ >12
- ☐ Other (Specify):

C2.2. For patients using fentanyl, what is the minimum time since last opioid use you typically require before starting buprenorphine in a non-pregnant patient without renal or hepatic dysfunction?

- ☐ No specific minimum time
- ☐ At least 12 hours
- ☐ At least 24 hours
- ☐ At least 36 hours
- ☐ At least 48 hours
- ☐ Other (Specify)

C2.3. What is the first buprenorphine dose (not total first day dose) you typically provide to start an induction for a non-pregnant patient without renal or hepatic dysfunction?

- ☐ 2 mg
- ☐ 4 mg
- ☐ 8 mg
- ☐ 16 mg
- ☐ Other (Specify):

C2.4. What is the maximum total first day buprenorphine dose you will provide to a non-pregnant patient without renal or hepatic dysfunction?

- ☐ 4 mg
- ☐ 8 mg
- ☐ 16 mg
- ☐ 24 mg
- ☐ I do not have a set maximum; I will give as high a dose as is needed.
- ☐ Other (Specify):

C2.5. Are “comfort” (ancillary) medications offered as part of this protocol? ☐ No ☐ Yes

Home Induction Protocol

C3. Do you use a home buprenorphine induction protocol ☐ No ☐ Yes [IF NO SKIP TO D]

C3.1. For patients using fentanyl what is the minimum time since last opioid use you typically require before starting buprenorphine in a non-pregnant patient without renal or hepatic dysfunction?

- ☐ No specific minimum time
- ☐ At least 12 hours
- ☐ At least 24 hours
- ☐ At least 36 hours
- ☐ At least 48 hours
- ☐ Other (Specify):

C3.2. What is the first buprenorphine dose (not total first day dose) you typically provide to start an induction for a non-pregnant patient without renal or hepatic dysfunction?

- ☐ 2 mg

- ☐ 4 mg
- ☐ 8 mg
- ☐ 16 mg
- ☐ Other (Specify):

C3.3. What is the maximum total first day buprenorphine dose you will provide to a non-pregnant patient without renal or hepatic dysfunction?

- ☐ 4 mg
- ☐ 8 mg
- ☐ 16 mg
- ☐ 24 mg
- ☐ I do not have a set maximum; I will give as high a dose as is needed.
- ☐ Other (Specify):

C3.4. Are “comfort” (ancillary) medications offered as part of this protocol? ☐ No ☐ Yes

C3.5. During the last 6 months, what % of patients initiated on buprenorphine have been initiated with the home-induction protocol? ☐ 0% ☐ 1-9% ☐ 10-49% ☐ >50%

D. Characteristics of Patients with Opioid Use Disorder (OUD) Presenting for Buprenorphine Treatment

D1. During the last 6 months, approximately how many OUD patients have presented for buprenorphine treatment? _____

D2. These questions ask about self-reported substance use characteristics of OUD patients: a) presenting for buprenorphine treatment; and b) experiencing buprenorphine-precipitated withdrawal during the last 6 months. Please give your “best guess” estimates.

	OUD patients presenting for buprenorphine treatment (Estimated%)	Patients with observed or reported buprenorphine-precipitated withdrawal (Estimated%)
Report using <u>any</u> fentanyl on a regular basis	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Report using <u>exclusively</u> fentanyl as their only opioid of use	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Report IV fentanyl/opioid use	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%

D3. These questions ask about urine drug test results of OUD patients: a) presenting for buprenorphine treatment; and b) experiencing buprenorphine-precipitated withdrawal during the last 6 months. Please give your “best guess” estimates.

	OUD patients presenting for buprenorphine treatment (Estimated%)	Patients with observed or reported buprenorphine-precipitated withdrawal (Estimated%)
Have an initial urine drug toxicology test positive for fentanyl	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Have an initial urine drug toxicology test positive for fentanyl <u>and</u> negative for all other opioids?	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Have an initial urine drug toxicology test positive for other non-opioid substances	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Most prevalent non-opioid substance detected on initial urine drug toxicology	<input type="checkbox"/> Benzodiazepines <input type="checkbox"/> Cocaine <input type="checkbox"/> Marijuana <input type="checkbox"/> Methamphetamine <input type="checkbox"/> Other (Specify):	<input type="checkbox"/> Benzodiazepines <input type="checkbox"/> Cocaine <input type="checkbox"/> Marijuana <input type="checkbox"/> Methamphetamine <input type="checkbox"/> Other (Specify):

D4. These questions ask about demographic characteristics of OUD patients: a) presenting for buprenorphine treatment; and b) experiencing buprenorphine-precipitated withdrawal during the last 6 months. Please give your “best guess” estimates.

	OUD patients presenting for buprenorphine treatment (Estimated%)	Patients with observed or reported buprenorphine-precipitated withdrawal (Estimated%)
Most common age	<input type="checkbox"/> <25 <input type="checkbox"/> 25-39 <input type="checkbox"/> 40-55 <input type="checkbox"/> >55	<input type="checkbox"/> <25 <input type="checkbox"/> 25-39 <input type="checkbox"/> 40-55 <input type="checkbox"/> >55
Male	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Hispanic	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
African-American/Black?	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
American Indian/Alaskan Native?	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Asian?	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
Native Hawaiian/Other Pacific Islander?	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
White/Caucasian?	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%
More than one race/Bi-racial?	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%	<input type="checkbox"/> 0% <input type="checkbox"/> 1-25% <input type="checkbox"/> 26-50% <input type="checkbox"/> 51-75% <input type="checkbox"/> >75%

Thank you for your participation!